AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. FDA has accepted a supplemental Biologics License Application (sBLA) for ENHERTU (trastuzumab deruxtecan) and granted Priority Review for the treatment of HER2-positive early breast cancer patients with residual invasive disease following neoadjuvant HER2-targeted therapy. The filing, supported by DESTINY-Breast05 Phase III data showing a 53% reduction in invasive disease recurrence or death risk versus T-DM1, positions the HER2-directed ADC for curative-intent expansion in the largest breast cancer segment.
Regulatory Milestone
Item
Detail
Agency
U.S. Food and Drug Administration (FDA)
Application Type
Supplemental Biologics License Application (sBLA)
Review Designation
Priority Review
Product
ENHERTU (trastuzumab deruxtecan)
Drug Class
HER2-directed antibody-drug conjugate (ADC)
New Indication
HER2-positive early breast cancer (residual disease post-neoadjuvant therapy)
Partners
AstraZeneca + Daiichi Sankyo (joint development and commercialization)
Supporting Trial
DESTINY-Breast05 (Phase III)
PDUFA Date
[Anticipated Q2 2026 – Priority Review typically 6 months]
DESTINY-Breast05 Clinical Evidence
Endpoint
ENHERTU
T-DM1 (Comparator)
Clinical Benefit
Invasive Disease-Free Survival (IDFS)
92.4%
83.7%
Absolute benefit: 8.7 percentage points
IDFS Hazard Ratio
0.47
Reference
53% reduction in recurrence/death risk (p<0.0001)
95% Confidence Interval
0.34-0.66
—
Highly statistically significant
Subgroup Consistency
Benefit across all pre-specified subgroups
—
Broad applicability
Trial Design:
Population: HER2-positive early breast cancer with residual invasive disease after neoadjuvant HER2-targeted therapy (chemotherapy + trastuzumab ± pertuzumab)
Setting: Post-neoadjuvant (adjuvant) treatment to eliminate residual disease
Comparator: T-DM1 (ado-trastuzumab emtansine) – standard of care for residual disease
Targeted delivery of cytotoxic agent to HER2-expressing cells; high payload-to-antibody ratio (DAR ~8); membrane-permeable payload enables bystander effect
Approved Indications
HER2-positive metastatic breast cancer (2L+); HER2-low metastatic breast cancer; HER2-positive gastric cancer; HER2-mutant NSCLC
Differentiation
Superior efficacy vs. T-DM1 in metastatic setting; now demonstrating curative-intent benefit in early disease
Strategic Context & Market Impact
Factor
Implication
Early Breast Cancer Market
~60% of HER2+ patients have residual disease post-neoadjuvant; represents largest addressable ENHERTU population to date
T-DM1 Displacement
DESTINY-Breast05 establishes ENHERTU as new standard of care for residual disease; T-DM1 revenue erosion anticipated
Curative Intent
Adjuvant approval shifts ENHERTU from palliative to curative positioning; premium pricing justification
Revenue Forecast
Analysts project $5-7 billion incremental annual sales with early breast cancer indication; total ENHERTU franchise approaching $15 billion peak
Competitive Moat
High barrier to entry for biosimilars/ADC competitors; DXd payload technology platform protected
Competitive Landscape
Competitor
Product
Mechanism
Early Breast Cancer Status
ENHERTU Differentiation
Roche
Kadcyla (T-DM1)
HER2 ADC (maytansinoid payload)
Approved (residual disease)
Superior IDFS; bystander effect; better tolerability
Seagen/Pfizer
Tukysa (tucatinib) + trastuzumab
HER2 TKI + mAb
Approved (adjuvant HER2+)
Oral convenience vs. IV; ENHERTU efficacy advantage in head-to-head
AstraZeneca/Daiichi
ENHERTU
HER2 ADC (DXd payload)
sBLA accepted; Priority Review
First ADC with 53% recurrence reduction vs. T-DM1 in early disease
Regulatory & Commercial Outlook
Milestone
Timeline
Status
FDA Priority Review
Q2 2026
PDUFA decision anticipated (6-month review)
EU EMA Submission
2026
sBLA filing expected H1 2026
Commercial Launch
Q3-Q4 2026 (U.S.)
Immediate formulary access given Priority Review; oncology center education
Global Expansion
2026-2027
Japan, China NDA filings; reimbursement negotiations
Forward‑Looking Statements This brief contains forward‑looking statements regarding FDA approval timelines, commercial launch execution, and competitive positioning for ENHERTU in early breast cancer. Actual results may differ due to regulatory decisions, pricing negotiations, and manufacturing supply constraints.-Fineline Info & Tech
By Fineline Cube 